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Catechol-O-methyltransferase inhibition with
tolcapone reduces the “wearing oV” phenomenon
and levodopa requirements in fluctuating
parkinsonian patients
H Baas, A G Beiske, J Ghika, M Jackson, W H Oertel, W Poewe, G Ransmayr on behalf of
the study investigators (see appendix)
Abstract
Background—More than 50% of patients
with Parkinson’s disease develop motor
response fluctuations (the “wearing oV”
phenomenon) after more than five years
of levodopa therapy. Inhibition of
catechol-O-methyltransferase by tolca-
pone has been shown to increase levodopa
bioavailability and plasma elimination
half life, thereby prolonging the eYcacy of
levodopa.
Objectives—The primary objective was to
evaluate the eYcacy of tolcapone in
reducing “wearing oV” in levodopa
treated, fluctuating parkinsonian patients.
Secondary objectives included assessment
of reduction in levodopa requirements,
improvement in patients’ clinical status,
duration of improvements, and tolerabil-
ity of tolcapone.
Methods—In this multicentre, ran-
domised, double blind, placebo controlled
trial, 58 patients received placebo, 60
received 100 mg tolcapone three times
daily (tid), and 59 received 200 mg tolca-
pone tid, in addition to levodopa/
benserazide.
Results—After three months with 200 mg
tolcapone tid, “oV” time decreased by
26.2% of the baseline value, “on” time
increased by 20.6% (P<0.01 v placebo),
and the mean total daily levodopa dose
decreased by 122 mg from the baseline
dose of 676 mg (P<0.01). These responses
were maintained up to nine months. With
100 mg tolcapone tid, “oV” time decreased
by 31.5% (P<0.05), “on” time increased by
21.3% (P<0.01), and the mean total daily
levodopa dose decreased by 109 mg from
the baseline dose of 668 mg (P<0.05).With
200 mg tolcapone tid, unified Parkinson’s
disease rating scale motor and total scores
were significantly reduced, and quality of
life (sickness impact profile) scores were
significantly improved. Both dosages were
well tolerated. Dyskinesia was the most
often reported levodopa induced adverse
event. Diarrhoea was the most often
reported non-dopaminergic adverse event
and the most frequent reason for with-
drawal from the study: four patients in the
100 mg tolcapone tid group and six in the
200 mg tid group withdrew because of
diarrhoea.
Conclusion—Tolcapone prolongs “on”
time in fluctuating parkinsonian patients
while allowing a reduction in daily levo-
dopa dosage, thereby improving the eY-
cacy of long term levodopa therapy.
(J Neurol Neurosurg Psychiatry 1997;63:421–428)
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Motor disability in Parkinson’s disease results
primarily from the loss of dopaminergic input to
the striatum.1 2 Parkinson’s disease aVects one to
two people in 1000 of the general population
and 1% of people older than 65 years.3 The
mainstay of treatment for Parkinson’s disease
is levodopa (3,4-dihydroxy-L-phenylalanine),
which is combined with a peripheral dopa
decarboxylase inhibitor (benserazide or carbi-
dopa) to prevent excessive peripheral levodopa
metabolism.4
Although levodopa remains the single most
eVective antiparkinsonian drug available, more
than half of all patients treated with levodopa
for longer than five years experience complica-
tions such as dyskinesia and motor fluctua-
tions, with progressively shortened periods of
benefit from each dose, which in turn often
necessitates more frequent levodopa doses.5 6
The mechanisms underlying this “wearing
oV” phenomenon are not fully understood but
are at least partially connected with the periph-
eral pharmacokinetics of levodopa and its rela-
tively short plasma elimination half life (about
1.5 hours).
Various pharmacological strategies have
been used to smooth out these response
fluctuations, including sustained release levo-
dopa preparations, add on therapy with depre-
nyl or orally administered dopamine agonists,
and subcutaneous apomorphine injections or
infusions.7–11
Despite the addition of a peripheral decar-
boxylase inhibitor, levodopa is extensively
metabolised in the periphery to 3-O-
methyldopa (3-OMD) by catechol-O-
methyltransferase (COMT).4 12 13 COMT
thereby reduces the amount of levodopa avail-
able for conversion to dopamine. More specu-
latively, the resulting 3-OMD, which has an
elimination half life of about 15 hours,
accumulates in the plasma and can compete
with levodopa for transport across the blood-
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brain barrier because these agents share a satu-
rable carrier for membrane transport.14–16
Tolcapone (3,4-dihydroxy-4-methyl-5-nitro-
benzophenone) is a potent, selective, reversible
inhibitor of COMT.17 In animal studies, tolca-
pone has been shown to inhibit COMT activity
in the gut, liver, and brain,18–20 and single oral
doses of up to 800 mg were shown to be well
tolerated in humans.6 Pharmacological interac-
tion studies of tolcapone and levodopa/
decarboxylase inhibitor in healthy volunteers21
showed that tolcapone roughly doubled the
estimated area under the concentration-time
curve and elimination half life of levodopa,
whereas the average peak concentration re-
mained unaVected. At the same time, the area
under the curve for 3-OMDwas reduced by up
to 80%. By increasing the bioavailability of
levodopa while maintaining more stable
plasma concentrations, tolcapone could en-
hance the eYcacy of levodopa therapy. Indeed,
previous short term clinical studies have shown
that the addition of tolcapone to levodopa
therapy reduced “oV” time and increased “on”
time over a six week period in fluctuating par-
kinsonian patients.22 23
The primary aim of the present study was to
assess the eYcacy of tolcapone in reducing
“wearing oV” type motor fluctuations in
parkinsonian patients receiving levodopa/
benserazide therapy. Secondary objectives in-
cluded evaluating the eVect of tolcapone on
levodopa requirements and the patients’ clini-
cal status, the duration of these responses to
tolcapone, and the tolerability of tolcapone
when coadministered with levodopa/
benserazide.
Materials and methods
STUDY DESIGN
This randomised, double blind, placebo con-
trolled study was conducted at 24 centres in
Europe and involved 177 patients from whom
informed consent had been obtained. The trial
was conducted in accordance with either the
Declaration of Helsinki and its amendments or
the laws and regulations of the country in
which it was performed, whichever gave the
patient greater protection.
Patients were screened for eligibility within
the four weeks before randomisation. During
this period, their antiparkinsonian therapy was
stabilised. In addition, their ability to complete
“on/oV” self rating charts correctly (giving rat-
ings for “on” and “oV” time as a proportion of
the waking day) was assessed because this
evaluation method,24 which is now widely used
in clinical trials, is essential in assessing the
impact of treatment. Furthermore, in a previ-
ous study,25 data from patient diaries showed
good correlation with data from investigators’
assessments of actual motor performance.
Patients were given examples and instructions
on how to complete the self rating charts and
had to complete accurately six charts on any
three typical days during each of the two weeks
before baseline to be eligible for inclusion in
the study. If more than six charts were
completed, only the last three from each week
were used for analysis to minimise bias.
Eligible patients were randomised to receive
either placebo or 100 or 200 mg tolcapone
three times daily (tid) The study had a
common closing date design and was planned
to end when all patients had received test
medication for three months (the primary end
point) and at least 30% had completed a 12
month assessment. However, only 15%
reached the 12 month assessment because of
the common closing date, so a secondary end
point of nine months was selected instead for
maintenance of response analyses of the 38%
of patients who reached this time point.
PATIENTS
Patients of either sex with at least two of the
three cardinal features of Parkinson’s disease
(bradykinesia, resting tremor, and rigidity) and
who exhibited predictable end of dose motor
fluctuations in response to levodopa therapy
were recruited to the study.
Eligible patients were at least 30 years old at
the onset of symptoms, had been treated with
levodopa for at least one year, had shown clear
improvement in the clinical features of Parkin-
son’s disease with this treatment, and had been
on a stable regimen of levodopa/benserazide
and any other antiparkinsonian drugs for at
least four weeks. Women were either post-
menopausal or using a reliable method of con-
traception.
Patients with non-idiopathic parkinsonism
(for example, progressive supranuclear palsy,
striatonigral degeneration, or sporadic olivo-
pontocerebellar atrophy) were excluded, as
were patients who exhibited sudden, unpre-
dictable “on/oV” fluctuations or diphasic dyski-
nesia. Those who had a mini mental state
examination score of 25 or less, who had had a
major depressive episode in the preceding six
months, or had a psychiatric or medical condi-
tion that might place them at increased risk or
interfere with assessment of Parkinson’s dis-
ease, or who had undergone neurosurgery dur-
ing the previous year were excluded. Treatment
with any of the following medications also
resulted in exclusion from the present study: a
centrally acting dopamine antagonist during
the preceding six months (the peripherally act-
ing dopamine antagonist domperidone was
permitted), a monoamine oxidase inhibitor
(except selegiline) in the preceding two
months, apomorphine in the preceding seven
days, or any investigational agent within the
preceding four weeks (or within five half lives of
the compound, whichever was longer).
TREATMENT
Tolcapone dosages of 100 and 200 mg tid
(administered orally) were selected on the basis
of pharmacokinetic results from multiple dose
studies in healthy volunteers,6 26 which indi-
cated that the clinical eVect of tolcapone shows
a plateau at these dosages. Riboflavin (0.5 mg)
was included in the placebo tablets to mimic
the yellow discoloration in urine that occurs
with tolcapone as a harmless side eVect. The
first daily dose of tolcapone or placebo was
taken with the first dose of levodopa; the
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remaining two doses were taken at six hourly
intervals thereafter.
After the first day of study treatment, the
levodopa dosage could be adjusted as neces-
sary, according to patient response and the
development of adverse eVects. However, levo-
dopa adjustment was not permitted during the
two weeks preceding the three month assess-
ment, so that the eYcacy of tolcapone could be
assessed under a stable levodopa regimen at the
primary end point. Increases in daily levodopa
dosage above the baseline level were not
permitted before month 3.
STUDY ASSESSMENTS
The eYcacy and tolerability of tolcapone were
assessed at the clinic between weeks 1 and 2
and at the end of week 6 and months 3, 6, 9,
and 12.
The primary eYcacy index was the change in
proportion of “on” and “oV” time between
baseline and month 3; this was measured using
self rating charts, which the patients completed
during a 16 hour period on any three typical
days during the week before each clinic visit.
Patients were required to provide ratings each
hour for the two preceding 30 minute periods.
A carer was allowed to assist the patient in
marking the diary, but the patient had to decide
on the ratings. Mobility was rated as “on”
(good or practically normal mobility), “inter-
mediate” (neither “on” nor “oV”), or “oV”
(stiVness, decrease in mobility or immobility).
The individual values for “on”, “intermedi-
ate”, and “oV” periods were calculated as a
percentage of a standardised 16 hour waking
day.
For the secondary indices, investigator’s glo-
bal assessments (IGAs) were used to evaluate
the degree of change between pretreatment
and post-treatment—that is, the overall efficacy
of tolcapone, compared with placebo, at the
primary end point. The investigators used nine
point scales to describe the severity of parkin-
sonian symptoms, the “wearing oV” phenom-
enon, overall eYcacy, and overall tolerance,
ranging from 4 (very marked improvement) to
−4 (very marked deterioration), and a seven
point scale to evaluate dyskinesia, from 3
(marked reduction) to −3 (marked increase).
The unified Parkinson’s disease rating scale
(UPDRS) was used to provide quantitative and
qualitative measures of the severity of Parkin-
son’s disease. At screening, baseline, and
subsequent clinical visits, scores from UPDRS
subscales I (mentation, behaviour, and mood),
II (activities of daily living during “on” and
“oV” periods), and III (motor function during
“on” periods) were assessed.
The sickness impact profile (SIP) was
completed by patients at baseline and at the
three and 12 month visits and was used to
evaluate patients’ quality of life. The SIP27
comprises 136 items considering 12 distinct
domains of quality of life: ambulation,mobility,
body care, social interaction, communication,
alertness, emotions, sleep, eating, work, house-
hold management, and recreation. In addition
to scores for each of the 12 domains, summary
scores were calculated for physical, psychoso-
cial, and total behavioural dysfunction. Details
of total daily levodopa dosage were recorded at
all assessment visits.
Adverse events were evaluated by spontane-
ous reports and observation of patients at
assessment visits. Patients were also asked to
rate the intensity of 13 levodopa induced
symptoms (including gastrointestinal,
neurological, cardiovascular, and psychiatric
disorders) if these had occurred during the four
days before the visit. Levodopa induced dyski-
nesia was assessed using UPDRS subscale IVa
and a five point dyskinesia rating scale, ranging
from 0 (no dyskinesia) to 4 (violent dyskinesia,
incompatible with normal motor tasks).
Vital signs (supine and standing pulse rate
and blood pressure), a 12 lead ECG, and labo-
Table 1 Baseline demographic data and key characteristics of Parkinson’s disease
Treatment group
Placebo
Tolcapone
100 mg tid 200 mg tid
Patients
Number 58 60 59
Male:female ratio (%) 60:40 52:48 56:44
Age (y) 64 (8) 62 (10) 63 (9)
Disease duration (y) 10.5 (5.5) 9.0 (5.0) 10.0 (4.8)
Total daily levodopa dose (mg) 660.5 (46.6) 667.5 (41.5) 675.8 (42.4)
Duration of levodopa treatment (y) 9.0 (5.1) 8.0 (5.1) 9.0 (4.5)
Hoehn and Yahr stage
“On” (patient %)
0-1.5 16 15 7
2 24 37 44
2.5 22 17 12
3-4 38 31 37
“OV” (patient %)
1-1.5 2 6 3
2 2 7 2
2.5 12 15 10
3-5 84 71 85
UPDRS total score 35.5 (18.1) 33.4 (16.7) 33.9 (18.0)
Where applicable, data are means (SD); tid = three times daily; UPDRS = unified Parkinson’s
disease rating scale.
Table 2 EYcacy data assessed by changes in “on/oV” time and total daily levodopa dose
and by IGAs of eYcacy at the primary endpoint
Treatment group
Placebo
(n=58)
Tolcapone
100 mg tid
(n=60)
200 mg tid
(n=59)
“On”time (% of day):
Baseline 53.4 (2.8) 50.8 (2.5) 52.4 (2.5)
Month 3 52.6 (3.6) 62.0 (3.3) 63.3 (3.3)
Change −0.7 (2.8) 10.8 (2.6)** 10.8 (2.6)**
“OV”time (% of day):
Baseline 37.8 (2.4) 40.3 (2.1) 37.4 (2.2)
Month 3 33.5 (3.0) 27.0 (2.7) 27.7 (2.7)
Change −4.2 (2.3) −12.7 (2.1)* −9.8 (2.1)
Total daily levodopa dose (mg):
Baseline 660.5 (46.6) 667.5 (41.5) 675.8 (42.4)
Month 3 633.2 (43.2) 558.4 (38.5) 551.2 (39.3)
Change −28.9 (26.2) −108.9 (23.4)* −122.2 (23.9)**
IGA of severity of Parkinson’s disease
(patients n (%)):
Improvement 15 (29) 40 (75)** 40 (73)**
No improvement 36 (71) 13 (25) 15 (27)
IGA of the “wearing oV” phenomenon
(patients n (%)):
Improvement 19 (37) 39 (74)** 41 (75)**
No improvement 32 (63) 14 (26) 14 (25)
IGA of overall eYcacy (patients n (%)):
Improvement 19 (37) 37 (70)** 43 (78)**
No improvement 32 (63) 16 (30) 12 (22)
* P < 0.05; ** P < 0.01 v placebo.
Data are means (SEM) for “on” and “oV” time and means (SD) for levodopa dosage.
IGA=investigator’s global assessment.
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ratory variables were recorded at clinic visits
throughout the study and data were screened
for values outside the predetermined normal
ranges.
STATISTICAL ANALYSES
EYcacy and tolerability analyses were per-
formed on all patients who had been ran-
domised to treatment, who had taken at least
one dose of study medication, and who were
subsequently seen at least once (the intention
to treat population). The Bonferroni-Holm
procedure was applied for pairwise compari-
sons of eVficacy between placebo and each
dosage of tolcapone to adjust for multiple
comparisons. The continuous variables (“on/
oV” time,UPDRS total, and subtotal scores for
subscales I to III, SIP scores, total daily
levodopa dose, and number of daily levodopa
doses) were analysed using two way analysis of
covariance (ANCOVA) techniques.
For each treatment, we report least squares
estimates of the mean treatment eVects—that
is, unweighted averages of centre means with
the covariate at its mean value. The categorical
variables (IGAs) were analysed by the
Cochran-Mantel-Haenszel test, using centre as
a stratification factor. The Breslow-Day test for
homogeneity was applied for paired compari-
sons to test for consistency of response
outcome across centres.
Results
After randomisation, 58 patients received
placebo, 60 received 100 mg tolcapone tid, and
59 received 200 mg tolcapone tid. Table 1
shows the baseline demographic data, key Par-
kinson’s disease characteristics, and levodopa
dosage.
EFFICACY
Primary measures at three month end point
With 100 mg tolcapone tid, “on” time
increased by 21.3% of the baseline value
(P<0.01 v placebo) and “oV” time decreased
by 31.5% (P<0.05). With 200 mg tolcapone
tid, “on” time increased by 20.6% (P<0.01)
and “oV” time decreased by 26.2% of the
baseline value (non-significant). Table 2 and
figure 1 summarise the eYcacy data showing
alleviation of the “wearing oV” phenomenon
and the change in daily levodopa dosage at the
primary end point.
Secondary measures at three month end point
The least squares mean (SD) reductions in
total daily levodopa dose were 108.9 (23.4) mg
(P<0.05) in the 100 mg tolcapone tid group
and 122.2 (23.9) mg (P<0.01) in the 200 mg
tid group. Both decreases were significantly
diVerent from the 28.9 (26.2) mg levodopa
reduction found with placebo.
Scores on UPDRS subscales I (mentation)
and II (activities of daily living) did not change
significantly between baseline and month 3 in
each of the three groups. The score for UPDRS
subscale III (motor function) was reduced by
2.1 (1.1) in the placebo group, 4.2 (1.0) in the
100 mg tolcapone tid group (not significant),
and 6.5 (1.0) in the 200 mg tid group
(P<0.01).
Least squares mean reductions in SIP total,
physical, and psychosocial scores between
baseline and month 3 were greater with
tolcapone than with placebo, indicating an
improvement in quality of life with tolcapone
during this period. Total SIP scores were
reduced by 0.9 (0.9) in the placebo group, 1.9
(0.9) in the 100 mg tolcapone tid group, and
4.2 (0.8) in the 200 mg tid group (P<0.05).
Physical scores were reduced by 2.2 (1.2) with
placebo, 3.2 (1.1) with 100 mg tolcapone tid,
and 5.0 (1.1) with 200 mg tid. Psychosocial
scores were reduced by 1.2 (1.3) with placebo,
1.3 (1.2) with 100 mg tolcapone tid, and 4.7
(1.2) with 200 mg tid (P<0.01).
Table 2 shows the IGAs of eYcacy. The IGA
of overall eYcacy of parkinsonian treatment
showed that, by month 3, significant changes
from baseline occurred in both tolcapone
groups compared with placebo (P<0.01).
Overall eYcacy was improved in 70% of
patients in the 100 mg tolcapone tid group and
in 78% in the 200 mg tid group, compared with
only 37% in the placebo group. The incidence
of “very marked improvement” was found to
be greatest with 200 mg tolcapone tid
Figure 1 EYcacy results at month 3, assessed by changes
in (A) “on“ time, (B) “oV” time, and (C) daily levodopa
dose. Data are least squares means (SEM). “On” time and
“oV” time are presented as a percentage of the 16 hour
waking day. *P < 0.05; **P < 0.01 v placebo.
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Secondary measures until nine month end point
We originally planned to evaluate maintenance
of response at the last time point at which at
least 30% of patients were still receiving
treatment—that is, 12 months. However, be-
cause the common closing date of the study
resulted in more patients receiving study treat-
ment for nine months (29% of the placebo
group, 39% of the 100 mg tolcapone tid group,
46% of the 200 mg tid group) than for 12
months (14% of the placebo group, 17% of the
100 mg tolcapone tid group, 15% of the tolca-
pone 200 mg tid group) we selected a second-
ary time point of nine months, thereby
maintaining our originally planned sample size.
Figure 2 shows the results of these mainte-
nance of response analyses.
With 200 mg tolcapone tid, the increase in
“on” time, decrease in “oV” time, and reduc-
tion in levodopa dosage found at month 3 were
maintained until month 9.
With 100 mg tolcapone tid, only the
decrease in “oV” time was maintained until
month 9.
TOLERABILITY
Both tolcapone dosages were generally well
tolerated. Table 3 shows the adverse events that
were reported at least 5% more often by
patients receiving tolcapone than by those
receiving placebo. Many of these (dyskinesia,
nausea, vomiting, insomnia, orthostatic com-
plaints, muscle cramps, excessive dreaming,
and somnolence) are known to occur with
levodopa therapy in patients with fluctuating
Parkinson’s disease. The principal non-
dopaminergic events reported were diarrhoea,
headache, and abdominal pain.
Twenty seven patients withdrew prematurely
from the study because of adverse events: four
(7%) from the placebo group, 14 (23%) from
the 100 mg tolcapone tid group, and nine
(15%) from the 200 mg tid group. Of the
adverse events leading to withdrawal, only
diarrhoea had a higher incidence with tolca-
pone than with placebo. No patients in the pla-
cebo group withdrew because of diarrhoea,
compared with four (7%) in the 100 mg tolca-
pone tid group and six (10%) in the 200 mg tid
group. These withdrawal rates were similar to
the number of reports of severe diarrhoea:
none in the placebo group, three of nine cases
with 100 mg tolcapone tid, and six of 15 cases
with 200 mg tid Although dyskinesia was the
most often reported levodopa induced adverse
event from the start of the study, it resulted in
the withdrawal of only two patients (one from
each tolcapone treatment group). Hallucina-
tions led to the withdrawal of two patients in
the 100 mg tolcapone tid group and one
patient in the 200 mg tid group. Orthostatic
hypotension led to the withdrawal of only one
patient overall (from the 100 mg tolcapone tid
group).
Most patients exhibited levodopa induced
dyskinesia at baseline: 57% in the placebo
group, 66% in the 100 mg tolcapone tid group,
and 69% in the 200 mg tid group, according to
the dyskinesia rating scale. No significant
changes in incidence from baseline were found
in any group during the study. The UPDRS
subscale IVa scores indicated that changes in
severity and duration of dyskinesia did not
reach significance in any group. The IGA of
dyskinesia at month 3 showed that dyskinesia
increased in 9% of patients receiving placebo,
compared with 32% in the 100 mg tolcapone
tid group and 40% in the 200 mg tid group.
Decreased dyskinesia occurred in 7% of
patients in the placebo group, 16% in the
tolcapone 100 mg tid group, and 18% in the
200 mg tid group.
Additional analyses were performed to assess
the temporal characteristics of the prevalence
rate of the adverse events dyskinesia and
diarrhoea. Analysis of the prevalence of dyski-
nesia at monthly intervals for the first nine
months of the study (fig 3) shows that the risk
of dyskinesia was highest in the first 29 days of
the study in all three groups; thereafter the risk
decreased dramatically in all groups between
days 30 and 59. After day 59, only eight new
cases of dyskinesia were reported: four in the
100 mg tolcapone tid group, two in the 200 mg
tid group, and two in the placebo group. Simi-
larly, analysis of the prevalence of diarrhoea
during the first nine months of the study (fig 3)
shows that the risk of developing diarrhoea
decreased with time in both tolcapone groups.
Figure 2 Maintenance of response up to month 9, assessed
by changes in (A) “on” time, (B) “oV” time, and (C) total
daily levodopa dose. “On” time and “oV” time are
presented as a percentage of the 16 hour waking day. Data
are means (SEM).
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Of the nine cases of diarrhoea reported in the
100 mg tolcapone group, the onset of four
cases was reported in each of months 1 and 2.
Of the 15 cases reported with 200 mg
tolcapone tid, five started in month 1, four in
month 2, and four in month 3. Analysis of the
hazard rates showed that, with 100 mg
tolcapone tid, the risk of developing diarrhoea
was about 7% during the first 59 days of treat-
ment, hereafter the risk decreased; no new
cases were reported after day 89. With 200 mg
tolcapone tid, the risk was about 8% until day
89, hereafter it decreased; no new cases devel-
oped after day 179. No treatment related
diVerences in vital signs and ECG results were
found between the study groups. For most
laboratory tests, mean values at baseline and all
assessment points and mean changes from
baseline were similar for all treatment groups.
However, with 200 mg tolcapone tid, mean
concentrations of aspartate aminotransferase
(AST) and alanine transferase (ALT) were
higher at week 6 than with placebo, before
reverting to baseline values for the remainder
of the study. Highly abnormal ALT concentra-
tions were found in three patients (one in the
100 mg tolcapone tid group, two in the 200 mg
tid group), all of whom had concomitantly high
AST concentrations. One of these patients
(from the 200 mg tolcapone tid group)
withdrew on day 113 of the study because of
raised liver transaminases. At an assessment on
day 118, this patient’s ALT concentration was
103 µm/l and AST was 41 µm/l; both transami-
nase activities declined gradually thereafter
until AST was within the standard reference
range by day 147 and ALT by day 169. This
patient was the only one to withdraw from the
study because of pronounced laboratory ab-
normalities; these were considered by the
treating physician to be probably related to tol-
capone treatment.
Discussion
The present study confirms and extends previ-
ous findings28 29 that tolcapone enhances the
eYcacy of levodopa. Whereas initial studies
were focused on single dose6 or short term (one
to six weeks) multiple dose22 26 coadministra-
tion of tolcapone with levodopa/decarboxylase
inhibitor, the present study showed that multi-
ple dose (tid) treatment with tolcapone results
in reduced severity of “wearing oV” type motor
fluctuations in levodopa treated patients for
three months and that this response is
maintained over time.
Treatment with tolcapone significantly de-
creased mean “oV” time (by >20%) and
increased mean “on” time (by >25%), com-
pared with placebo. Analysis of primary end
point “on/oV” data disclosed that both tolca-
pone dosages were equally eVective in increas-
ing “on” time, but the 100 mg tid dosage was
more eVective in decreasing “oV” time. How-
ever, the mean reduction in levodopa dosage by
month 3 was greater with 200 mg tolcapone tid
than with 100 mg tid This reduction was
maintained until the nine month end point
only with the higher tolcapone dosage; possibly
the failure to find significant results at this
point was due to the smaller sample size.
A small but significant reduction (compared
with placebo) in UPDRS motor and total
scores and in quality of life measures (SIP total
and psychosocial scores) was found at month 3
with 200 mg tolcapone tid. The IGA of
eVficacy also showed significant overall im-
provements in eYcacy of treatment with both
tolcapone dosages.
Although an increase in “on” time would, by
implication, lead to increased duration of
dyskinesia, the overall proportion of patients
exhibiting levodopa induced dyskinesia of a
particular duration or intensity did not increase
with either tolcapone dosage. This is most
likely a reflection of the concomitant decreased
levodopa dosage in patients treated with tolca-
pone. In addition, although dyskinesia oc-
curred early in the study, the incidence in the
tolcapone treatment groups diminished sub-
Table 3 Adverse events reported by patients on tolcapone with incidences >5% higher
than reported by patients on placebo
Treatment group (n (%))
Placebo (n=58)
Tolcapone
100 mg tid (n=60) 200 mg tid (n=59)
Dyskinesia* 12 (21) 22 (37) 31 (52.5)
Nausea* 8 (14) 16 (27) 17 (29)
Insomnia* 10 (17) 15 (25) 12 (20)
Orthostatic complaints* 6 (10) 16 (27) 12 (20)
Muscle cramps* 6 (10) 13 (22) 10 (17)
Excessive dreaming* 8 (14) 14 (23) 5 (8.5)
Diarrhoea 2 (3) 9 (15) 15 (25)
Somnolence* 5 (9) 12 (20) 7 (12)
Vomiting* 2 (3) 7 (12) 5 (8.5)
Headache 2 (3) 6 (10) 2 (3)
Akathisia/restlessness 0 (0) 3 (5) 4 (7)
Abdominal pain 1 (2) 1 (2) 4 (7)
Dyspnoea 1 (2) 0 (0) 4 (7)
Hypotension 0 (0) 2 (3) 3 (5)
*Corresponding to levodopainduced symptom check list used by investigators during the study;
tid = three times daily.
Figure 3 Prevalence rates of (A) dyskinesia and (B)
diarrhoea up to month 9. Rates are presented as the
percentage of patients reporting these adverse events at the
specified intervals.
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stantially with time before plateauing just
above the incidence in the placebo group.
Moreover, the risk of developing new dyski-
nesia decreased dramatically after the first
month of treatment. Further studies are
required to elucidate more fully any association
between tolcapone and levodopa induced dys-
kinesia because the present study was not
designed to quantify dyskinesia optimally.
Previously at these dosages, tolcapone had
been shown to increase levodopa bioavailability
up to twofold,6 so an increase in levodopa
induced adverse events was expected. How-
ever, only 12 patients treated with tolcapone
altogether withdrew from the trial because of
adverse events induced by levodopa, so these
were not considered to be treatment limiting.
Diarrhoea, which was reversible in all cases,
was the most often reported non-dopaminergic
event and the most often cited reason for
premature withdrawal: 10 patients altogether
withdrew because of diarrhoea, which resolved
soon after stopping treatment with tolcapone.
The incidence of diarrhoea was related to
tolcapone dosage. However, patients reporting
diarrhoea in the tolcapone groups usually did
so early in the study, and the prevalence rate of
diarrhoea decreased with time, indicating that
patients who had not developed diarrhoea dur-
ing the first six months of treatment were
unlikely to experience it thereafter. This side
eVect has been found to occur with another
second generation COMT inhibitor,
entacapone.30 The mechanisms responsible for
diarrhoea induced by COMT inhibition are
under investigation.
Raised liver transaminases were found in
only three patients, and, although the abnor-
malities were considered to be probably related
to tolcapone treatment, only one patient with-
drew from the study for this reason. This
patient was asymptomatic, and enzyme con-
centrations returned to normal within about
one month after treatment was withdrawn. The
underlying mechanism leading to this adverse
event is also unclear; the transaminase abnor-
malities found in the other two aVected
patients resolved without sequelae while they
were still receiving tolcapone.
In summary, tolcapone was significantly
more eVective than placebo in reducing the
“wearing oV” phenomenon and improving
overall clinical status and treatment eYcacy in
parkinsonian patients treated with levodopa.
Both dosages seemed equally eVective accord-
ing to the primary eYcacy measure (changes in
“on/oV” time), although secondary eYcacy
results (UPDRS and SIP scores) suggested
that 200 mg tolcapone tid was more eYca-
cious. However, the larger dosage was associ-
ated with greater incidences of adverse eVects
and premature withdrawals. Additional studies
are needed to ascertain which dosage will pro-
vide optimum long term benefit: risk ratios in
fluctuating patients. Results obtained in this
study suggest that a tolcapone dose of 200 mg
tid is not as well tolerated as the smaller dose
and should only be used if a satisfactory
improvement is not attained with 100 mg
tolcapone tid The present study nevertheless
provides evidence that tolcapone addresses the
need for an agent that compliments current
antiparkinsonian therapy, by extending the
period during which levodopa is eVective.
This study was supported by F HoVmann-La Roche
Ltd, Basel, Switzerland.It has been published as a con-
densed version in the Proceedings of the 4th Inter-
national Congress of Movement Disorders, Berlin:
Springer-Verlag, 1996
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NEUROLOGICAL STAMP
Jean Baptiste van Helmont (1577-1644)Keywords: Neurological stamp
Jean Baptiste van Helmont was the founder of the
iatrochemical school which looked to chemical explana-
tions of vital phenomena. He was a man of great
intellectual curiosity and studied philosophy at Louvain.
Disappointed with the content of the course he turned to
law and after further disappointment decided to study
medicine.
Van Helmont’s teaching revolved around two terms, Blas
and Gas. He was much influenced by the doctrines of
Paracelsus and, like Paracelsus, believed that each material
process of the body was presided over by a special spirit.
This he called Blas. Physiological processes were them-
selves chemical, being activated by a special ferment (or
Gas) and were also presided over by a special spirit. This
spirit, in turn, was governed by a sensory motor or sensitive
soul located in the folds of the stomach, especially its ori-
fice. It was thought that the duumvirate of stomach and
spleen regulated the functions of life and that when the
duumvirate “withdraws its government” epilepsies or other
diseases resulted. Van Helmont conceded that the
“occasional nest” of epilepsy could be in the head or feet.
Although the disease originated in the stomach he consid-
ered it could be provoked by strong emotions aVecting the
sensitive soul.
There was another disease which van Helmont thought
related to epilepsy. This was asthma. It had its original seat
in the duumvirate. It aVected and shook the whole body,
but then concentrated on the lungs—whereas epilepsy
made itself felt in the head. Van Helmont was so impressed
by the apparent analogy between the two diseases that he
stated “we may lawfully, therefore, by a Phylosophical Lib-
erty name an asthma the falling sickness of the lungs”.
Van Helmont believed in Paracelsus’ weapon salve,
which healed by anointing the weapon instead of the
wound. He became involved in a controversy regarding the
weapon salve and magnetic and sympathetic healing. In
1624 the Inquisition denounced his views and declared
him suspect of heresy. His chief work Ortus Medicinae was
published in 1648 after his death.
Van Helmont was honoured philatelically on a Belgium
stamp issued in 1942 (Stanley Gibbons 989, Scott B322).
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